Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $31.14

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $31.14.

A number of research analysts recently commented on CPRX shares. Stephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. Finally, Truist Financial raised their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

Catalyst Pharmaceuticals Stock Down 1.0 %

Shares of Catalyst Pharmaceuticals stock opened at $21.31 on Wednesday. The firm has a market capitalization of $2.54 billion, a P/E ratio of 18.06, a P/E/G ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $24.27. The firm’s 50 day moving average is $21.80 and its two-hundred day moving average is $19.77.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock worth $1,754,140 in the last quarter. Company insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its stake in shares of Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after buying an additional 263,099 shares in the last quarter. Pacer Advisors Inc. raised its position in Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after acquiring an additional 2,965,310 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after acquiring an additional 287,300 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Catalyst Pharmaceuticals by 4.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock worth $23,215,000 after purchasing an additional 50,804 shares in the last quarter. Finally, Mesirow Institutional Investment Management Inc. grew its stake in shares of Catalyst Pharmaceuticals by 29.9% during the 2nd quarter. Mesirow Institutional Investment Management Inc. now owns 934,234 shares of the biopharmaceutical company’s stock worth $14,471,000 after purchasing an additional 215,130 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.